Accessibility Menu
Ono Pharmaceutical logo

Ono Pharmaceutical(OTC) OPHLF

Market Cap$6.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-50%
5 Year-23%
1 Year+40%
1 Month-5%
$14.71
+0.00%
+0.00Today
Ono Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 14.712026-08-13
Ono Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.01%USD 14.862026-08-06
1 month-5.45%USD 15.562026-07-14
3 month+2.88%USD 14.302026-04-28
Year to date+16.31%USD 12.652025-12-23
1 year+40.43%USD 10.472025-08-13
3 year-9.71%USD 16.292023-08-10
5 year-23.3%USD 19.182021-07-30
Since inception-49.92%USD 29.382003-07-08

Ono Pharmaceutical Financials at a Glance

Market Cap

$6.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥506.29B

Net Income (TTM)

¥76.51B

EPS (TTM)

$1.06

P/E Ratio

13.93

Dividend

$0.52

Beta (Volatility)

0.09 (Low)

Price

$14.71

Volume

905

Open

$14.71

Previous Close

$14.71

Daily Range

$14.71 - $14.71

52-Week Range

$10.27 - $18.67

Estimated Earnings Date

Oct 29, 2026

OPHLF News

Dividends blackboard sketch doodle

How to Invest in Schwab International Dividend Equity ETF (SCHY)

Tony DongFeb 27, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. is a prominent player in the global pharmaceutical industry, focusing on the development, procurement, and commercialization of innovative therapeutic solutions. The company is particularly recognized for its extensive oncology product line and commitment to research and development across various therapeutic areas.

Products and Services
  • Key oncology treatments including OPDIVO, KYPROLIS, and BRAFTOVI
  • Medications for metabolic health, such as GLACTIV and FORXIGA
  • Therapeutics for autoimmune diseases, cardiovascular conditions, and neurological disorders
Growth Outlook
  • Active R&D pipeline targeting multiple oncological and autoimmune conditions
  • Recent quarterly revenue growth indicates strong market demand
  • Strategic focus on expanding therapeutic offerings enhances competitive positioning
Financial Highlights
  • Recent quarterly revenue of 119.5 billion JPY, reflecting robust sales performance
  • TTM net income of 82.3 billion JPY, showcasing profitability
  • Strong cash position with 238.5 billion JPY in cash and equivalents
Ono Pharmaceutical Co., Ltd. has established itself as a leader in the pharmaceutical sector, particularly in oncology. The company's diverse product portfolio addresses critical health issues, including cancer, metabolic disorders, and autoimmune diseases. With a strong emphasis on research and development, Ono is well-positioned to innovate and expand its offerings in the competitive healthcare landscape. Recent financial performance highlights a solid revenue stream and profitability, supported by a significant cash reserve, which provides the company with the flexibility to invest in future growth initiatives. The strategic focus on expanding therapeutic areas and enhancing product offerings is expected to drive continued growth and strengthen market presence.
AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

4,206

CEO

Gyo Sagara

Website

www.ono-pharma.com

Headquarters

Osaka, OS 541-8564, JP

OPHLF Financials

Key Financial Metrics (TTM)

Gross Margin

73.56%

Operating Margin

22.07%

Net Income Margin

15.13%

Return on Equity

9.08%

Return on Capital

10.63%

Return on Assets

7.04%

Earnings Yield

7.18%

Dividend Yield

3.55%

Payout Ratio

49.26%

Stock Overview

Market Cap

$6.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

469.91M

Volume

905

Avg. Volume

286.333

Financials (TTM)

Gross Profit

¥372.38B

Operating Income

¥111.64B

EBITDA

¥149.91B

Operating Cash Flow

¥135.57B

Capital Expenditure

-¥5.78B

Free Cash Flow

¥129.79B

Cash & ST Invst.

¥219.60B

Total Debt

¥116.25B

Ono Pharmaceutical Performance Analysis

Ono Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 3,301,177,9722.7%
20242024-03-31JPY 3,480,784,4685.4%
20252025-03-31JPY 3,193,636,134-8.2%
20262026-03-31JPY 3,422,774,3307.2%
Ono Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-303.1%
Q32025-12-316.5%
Q42026-03-31-14.7%
Q12026-06-30-3.5%
Ono Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 1.7018.1%
20242024-03-31JPY 1.858.3%
20252025-03-31JPY 0.70-62.2%
20262026-03-31JPY 0.9841.1%
Ono Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3028.8%
Q32025-12-3127.0%
Q42026-03-31-97.2%
Q12026-06-302886.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥115.32B

-9.6%

Gross Profit

¥86.85B

-4.1%

Gross Margin

75.31%

N/A

Market Cap

$6.91BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.64M

N/A

Employees

4,206

N/A

Net Income

¥23.98B

+35.7%

EBITDA

¥39.87B

+27.7%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥219.60B

+57.8%

Total Debt

¥116.25B

-15.8%

Accounts Receivable

¥130.05B

-9.4%

Inventory

¥55.35B

-21.8%

Long Term Debt

¥74.25B

-29.5%

Short Term Debt

¥42.00B

+27.8%

Return on Assets

7.04%

N/A

Return on Invested Capital

11.70%

N/A

Free Cash Flow

-¥929.23M

-182.7%

Operating Cash Flow

¥1.05B

-69.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KYKOFKyowa Kirin Co., Ltd.
$14.43+0.00%
GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited
$2.34+0.00%
HKMPYHikma Pharmaceuticals PLC
$45.36-1.86%
HKMPFHikma Pharmaceuticals PLC
$22.28+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.28+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.63-0.00%
ONDSOndas
$9.32+0.05%
INTCIntel
$103.46-0.01%

Questions About OPHLF

What is the current price of Ono Pharmaceutical?

Ono Pharmaceutical is trading at $14.71 per share.

What is the 52-week range for Ono Pharmaceutical?

Over the past 52 weeks, Ono Pharmaceutical has traded between $10.27 and $18.67.

How much debt does Ono Pharmaceutical have?

As of the most recent reporting period, Ono Pharmaceutical reported total debt of ¥720.50M.

How much cash does Ono Pharmaceutical have on hand?

Ono Pharmaceutical reported ¥1.35B in cash and cash equivalents in its most recent financial results.

What is Ono Pharmaceutical’s dividend yield?

Ono Pharmaceutical currently has a dividend yield of 3.55%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services